Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03203447 · ClinicalTrials.gov registry record · Phase 3
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO
A Phase 3 study, sponsored by Clearside Biomedical.
- Terminated
- Registry status
- Phase 3
- Development phase
- 325
- Enrollment target
NCT03203447 is a Phase 3 study that was terminated before completion, run by Clearside Biomedical. The registered enrollment target is 325 participants.
The verdict
NCT03203447, a Phase 3 study, was terminated before completion, sponsored by Clearside Biomedical.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 325 participants
- Enrollment target
Study Summary
This Phase 3, multicenter, randomized, masked, controlled, parallel group study is designed to demonstrate that suprachoroidal (SC) CLS-TA administered with intravitreal (IVT) anti-VEGF agent in subjects with treatment naive RVO is superior to IVT anti-VEGF agent used alone.
Interventions
- DRUG suprachoroidal CLS-TA
- DRUG suprachoroidal sham
- DRUG Lucentis or Avastin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 325 participants |
| Start Date | 2018-03-05 |
| Est. Completion | 2018-12-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03203447
The ClinicalTrials.gov registry entry for NCT03203447 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 325 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Clearside Biomedical, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which suprachoroidal CLS-TA is the first listed.
NCT03203447 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03203447 about?
NCT03203447 is a clinical study titled "Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO". This Phase 3, multicenter, randomized, masked, controlled, parallel group study is designed to demonstrate that suprachoroidal (SC) CLS-TA administered with intravitreal (IVT) anti-VEGF agent in subjects with treatment naive RVO is superior to IVT anti-VEGF agent used alone.
What is the current status of trial NCT03203447?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 325 participants. The study started on 2018-03-05. Estimated completion is 2018-12-18.
What interventions are being tested in trial NCT03203447?
The interventions under investigation include: suprachoroidal CLS-TA (DRUG), suprachoroidal sham (DRUG), Lucentis or Avastin (DRUG).
Who is sponsoring clinical trial NCT03203447?
This trial is sponsored by Clearside Biomedical, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.